PremiumRatingsBuy Rating for Tenaya Therapeutics Driven by Promising Clinical Developments and Strategic Restructuring Tenaya Therapeutics reports Q1 EPS (24c), consensus (20c) Promising Outlook for Tenaya Therapeutics: Buy Rating Justified by Innovative Gene Therapy Potential PremiumRatingsPromising Clinical Trial Results for TN-201 Support Buy Rating for Tenaya Therapeutics Promising Developments and Expert Endorsements Bolster Buy Rating for Tenaya Therapeutics Tenaya data further builds TN-201 profile, says H.C. Wainwright PremiumThe FlyTenaya Therapeutics files $300M mixed securities shelf Tenaya Therapeutics: Strong Financial Position and Promising Clinical Trial Results Justify Buy Rating Biotech Alert: Searches spiking for these stocks today 
